ResearcherChongqing Medical UniversityNo recent work listed

Li He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7015-1870; OpenAlex author ID A5100749506. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper

Papers 2

High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/mmr.2019.10869 ↗
An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. Last author DOI 10.3892/ol.2019.10596 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jianping Gong · 1 shared paper, 2020 · strength 0.16
- Paper High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma. DOI 10.3892/mmr.2019.10869 ↗
Yu Zeng · 1 shared paper, 2019 · strength 0.12
- Paper An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cispla… DOI 10.3892/ol.2019.10596 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.